• Profile
Close

Targeted therapy in advanced melanoma with rare BRAF mutations

Journal of Clinical Oncology Nov 23, 2019

Menzer C, Menzies AM, Carlino MS, et al. - In this study, 103 individuals with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were involved in order to determine the efficiency of targeted therapy in advanced melanoma with rare BRAF mutations. It was discovered that people with rare BRAF mutations can respond to targeted therapy, nevertheless, in comparison with V600E mutated melanoma, efficiency appears to be lower. Thus, for both V600 and non-V600 mutations, combination BRAFi/MEKi seems to be the best regimen. However, due to the heterogeneity of persons with small sample sizes for some of the reported mutations, interpretation should be carried out carefully.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay